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Abstract 
Depression is undisputedly common among individuals with End-Stage 
Kidney Failure and associated with adverse outcomes. It is well recognized that 
effective treatments for depression are needed within routine dialysis care. But, 
are we any closer to successfully treating depression in dialysis patients? We 
consider this question here with respect to two common treatments, anti-
depressant medication and Cognitive Behavioural Therapy (CBT). Currently, 
there are limited data from randomized placebo-controlled trials regarding the 
acceptability and efficacy of anti-depressants. CBT trials appear to show more 
consistent treatment effects, albeit the feasibility of routine delivery remains 
unknown. No studies in dialysis patients have evaluated the combined effects of 
CBT with anti-depressants. There is a need to consider pragmatic depression 
treatment trials in dialysis patients in order to increase study recruitment in order 
to have more reliable data from which to evaluate the evidence base. Furthermore, 
we need to understand why treatments work, and for whom do they work? Lastly, 
addressing issues surrounding treatment acceptability and implementation as part 
of regular care remain key challenges that require attention if we are to improve 
the mental health of individuals on dialysis. 
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Introduction 
There is a growing body of evidence demonstrating the association 
between depression and mortality among individuals with End-Stage Kidney 
Failure (ESKF). It is estimated that the presence of depressive symptoms is 
associated with a 50% increase in the risk of mortality1,2. This is particularly 
concerning given the high prevalence of depression, which is estimated to be 
approximately between 23-39%, depending on whether diagnostic or screening 
tools are used for evaluation3. Similar estimates of depression prevalence are also 
reported among individuals with a kidney transplant4. Furthermore, depression is 
also associated with other adverse outcomes, including increased hospitalization5, 
treatment non-adherence6 and increased inflammation and malnutrition7. Such 
factors may serve as candidate mechanisms underpinning the depression-
mortality relationship.  
Given the large body of evidence detailing the impact of depression among 
those on dialysis, developing a robust evidence base for treatment effectiveness 
is imperative if we are to improve mental health and patient outcomes. Here, we 
address the question; “Are we any closer to successfully treating depression in 
dialysis patients?” by considering the current evidence base with a focus on the 
two most common treatments modalities, anti-depressants and Cognitive 
Behavioural Therapy (CBT). Before this however, we begin by discussing the 
importance of treatment acceptability.  
 
Do dialysis patients want yet another set of treatment(s)? 
 Individuals receiving dialysis are prescribed a complex and demanding 
treatment regimen, including multiple medications and significant dietary and 
fluid restrictions. Given this complexity, non-adherence remains common to 
aspects of treatment, often for a variety of reasons including depression8 and 
unhelpful treatment beliefs9,10. In light of high levels of polypharmacy11 and 
significant treatment burden, it is understandable that undertaking additional 
treatment(s) for depression might be intolerable for some.  
 
A recent study investigated the acceptance of antidepressant treatment by 
haemodialysis (HD) patients and their renal team12, by evaluating patients 
randomized to the management arm of the Symptom Management Involving 
End-Stage Renal Disease (SMILE) trial13. As part of this trial, depression 
symptoms were evaluated monthly for a year using the Patient Health 
Questionnaire-9 (PHQ-9); PHQ-9 screening score 10 was employed to indicate 
possible depression. Of the 101 patients evaluated, 39 had depression on at least 
one or more of the monthly assessments. These 39 patients undertook 373 
depression screening assessments during the study. In 147 or these 373 
assessments depression was detectable.  In approximately 70% of these cases 
anti-depressants had been previously prescribed. In cases where health 
professions recommended intensified anti-depressant treatment, 70% of patients 
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did not accept the recommendation. At 44 assessments points, patients with a 
PHQ-9 score 10 were not receiving anti-depressants; in 91% of those cases 
patients refused treatment. The primary reason for refusal was the attribution of 
their depression to an acute event, chronic illness, or dialysis. Interestingly, in 18 
instances in which patients accepted the recommendation for treatment, 61% 
(n=11) of renal services were unwilling to provide treatment. No reasons for 
rejecting the treatment recommendation were given in 8 of the 11 instances12. 
 
Notwithstanding the complexity of this study and the identified limitations14, 
which includes the reliance on the PHQ-9 to indicate depressive cases, these data 
provide some striking insight into the acceptability of anti-depressant treatment. 
It suggests that both patients and renal staff are reluctant to initiate or modify anti-
depressant treatments. This is also reflected indirectly by the low consent rates 
observed in clinical trials of anti-depressant in kidney disease patients (discussed 
below). Efforts to provide better psychoeduction to patients and health care 
professionals might be one strategy to better support treatment decisions and 
overcome such barriers.  
 
Given that some patients refuse treatment on the basis of their illness and 
symptom attributions, specifically eliciting their illness and treatment beliefs and 
trying to alter them, might be of benefit. Indeed, Taylor et al15 argue that offering 
treatment interventions that are congruent with patient’s  illness beliefs and 
coping styles may promote uptake. Moreover, Taylor et al15 identified that 
treatment interventions that were explicitly linked with the illness label 
depression were deemed to be less acceptable to ESKF patients. Consideration 
of how a person’s emotional response to ESKF is identified and subsequently 
managed in a way that is acceptable to both patients and health care staff is 
therefore needed. This exploratory work is underway16 aiming to identify the 
needs and preferences of ESKF patients and likewise to identify the barriers and 
facilitators to the detection and management of depression by renal staff. 
Considering these factors will help to embed evidence-based treatments for 
depression as part of routine care.  
 
What is the evidence for anti-depressants in dialysis patients? 
According to the UK National Institute of Health and Care Excellence 
(NICE) depression guidelines, pharmacotherapy should only be used to treat 
patients who meet diagnostic criteria for moderate to severe symptoms of 
depression17. When prescribing drug treatments to manage depression in people 
with physical long-term conditions (LTC) the following factors need to be 
considered: (i) the potential for drug-drug interactions, (ii) the likely side effects 
of the medication, (iii) the patient’s previous history of pharmacotherapy 
treatments, (iv) patient preference, and (v) the toxicity of the drug and the risk of 
overdose among patients with suicidal ideation. 
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 Despite the ever-growing literature on depression in dialysis patients, 
there remains a remarkable lack of treatment studies. Most antidepressant trials 
in dialysis patients have focused on Selective Serotine Reuptake Inhibitions 
(SSRIs). Unfortunately, most studies examining the effectiveness of anti-
depressants have been small non-randomized studies18–26, albeit suggesting some 
potential efficacy. A recent non-placebo-controlled study compared paroxetine 
and agomelatine (an atypical anti-depressant) in a sample of chronic kidney 
disease (CKD) patients, reported a similar treatment response by 4 weeks27. By 8 
and 12 weeks however, depression scores were significantly lower in those 
treated with agomelatine. There were no serious adverse events and side effect 
profiles for each drug were reportedly similar27.  
To date, there have only been three randomized placebo-controlled trials 
of an antidepressant agent in individuals with kidney disease28–30, of which two 
studies were in dialysis patients. The first, in 14 HD patients found no significant 
improvement in depression symptoms after an 8 week treatment with fluoxetine 
compared with  placebo28. The most recent study in HD patients was a feasibility 
randomized placebo-controlled trial of sertraline by Friedli et al29. Of 1353 
patients approached for depression screening, 243 were excluded due to inability 
to read English. 64% consented to be screened (n=709) with 32% (n=231) 
screening positive using a Beck Depression Inventory of 16. 68 (29%) were 
ineligible for the trial phase because of current treatment for depression. 63 
patients gave further consent to be assessed by the study psychiatrist who 
diagnosed major depressive disorder in 37 (58.7%) of patients. 30 patients were 
randomized (n=15 in each), half the recruitment target specified in the study 
protocol31. There were no significant nor clinically meaningful differences in the 
change of depression symptoms between the two-arms, albeit the study was 
drastically underpowered. Drop-outs due to adverse events were considerably 
higher in the Sertraline arm compared to the placebo arm (7 in the sertraline arm, 
2 in the placebo arm). Overall, the study clearly demonstrated the problems with 
conducting a trial of this particular design31 since a relatively high proportion of 
patients were already taking anti-depressants. Modification of trial design to 
allow inclusion of patients already receiving treatment is one recommendation to 
improve trial feasibility through getter eligibility.   
RCTs on drug therapy of depression in dialysis patients are thus greatly 
limited. Expanding the target patient population to CKD in general does not add 
much to our knowledge of this area. Similar issues of scale and feasibility were 
apparent in a much larger randomized placebo-controlled trial of sertraline in 
CKD patients30. 977 of 14,658 CKD patients screened positive for depression. 
201 were consented and randomized to either sertraline (n=102) or placebo 
(n=99) arms. Over a 12-week follow-up there were no significant differences 
between the treatment arm and placebo with regards to depression scores. 
Remission rates were also similar at 15%, as was end of follow-up health related 
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quality of life and function scores. Those in the sertraline arm reported 
significantly more side effects compare with the placebo arm. Thus, the study 
offered no support for the use of sertraline for major depression in CKD and 
parallels can be drawn with Friedli et al 29 since both studies required a very large 
screening samples.  
 
Cognitive behavioural therapy (CBT) 
Treatment options for depression in dialysis patients are not restricted to 
anti-depressants agents. Talking therapies, particularly CBT might well have 
advantages in terms of acceptability to those are reluctant to take anti-depressants 
and should be considered for individuals with mild to moderate symptoms of 
depression17. Two meta-analyses exploring the effectiveness of psychological 
talking therapies (including CBT) for the management of depression in people 
with coronary heart disease32 and diabetes33 showed that these types of 
interventions improve depressive symptoms. However, the size of improvements 
in depressive symptoms was relatively small. This likely reflects the need to 
refine psychological treatments further to manage illness specific beliefs and 
challenging treatment demands and health consequences that present uniquely for 
each LTC 34.  
Three randomized controlled trials have tested the efficacy of CBT for 
depression in HD patients. The first study compared a 12 week group CBT 
treatment (n=41) to a control arm (n=43) and reported significant improvements 
in depressive symptoms and quality of life35 over a 9 month follow-up. Although 
a relatively small study, consent rates were impressive compared to the 
aforementioned drug trials. A total of 350 patients were screened for eligibility, 
with 100 identified as depressed with 90 randomized (46 to the intervention arm 
of which 41 started CBT treatment).  
In the second study, individual CBT administered in the dialysis centre 
(n=26), significantly improved depression symptoms, quality of life and daily 
fluid adherence compared with a waiting list control  group (n=33)36. The third 
study compared five-weeks of individual CBT with usual care in 60 dialysis 
patients with mild to moderate depression and anxiety symptoms37. Statistically 
significant effects of CBT on depression and anxiety outcomes were observed 
post treatment and after nine-weeks of follow-up. 
A secondary analysis of data from a RCT testing the efficacy of a brief 
self-management intervention showed that compared with usual care, those in the 
intervention arm had significantly fewer depression symptoms over a 12 month 
follow-up38. Intriguingly, the intervention was designed to target self-
management behaviour, through the use of behaviour change techniques, and did 
not include components that target emotional regulation. It could be that the 
intervention achieved its effects via increasing personal resources, resilience and  
self-efficacy38.  
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Although CBT has shown promise for improving depressive symptoms, 
how easily CBT treatment protocols can be administered as part of routine 
dialysis care remains unknown. Efforts to look at the optimal delivery methods 
are therefore required. One option might be internet delivered CBT (iCBT). The 
feasibility of iCBT for use in HD patients was first evaluated in a non-randomized 
controlled single group design, with 22 patients receiving a 8 week on-line CBT 
intervention, with therapist support39. Consent rates were reassuring, with 22 of 
30 patients assessed for study eligibility starting the intervention, 20 followed up 
post treatment and 17 at 3 months follow-up. Clinically significantly 
improvements were observed for both depression (34%) and anxiety (31%).  
A recent study assessed the feasibility of delivering online CBT, with or 
without therapist telephone support, for psychological distress (mild to moderate 
depression and anxiety symptoms) in HD patients40. Of the 410 patients 
approached, 182 (44%) completed screening measures. 26% of patients found 
screening unacceptable; and a further 30% found it unfeasible. Psychological 
distress was detected in 101 (55%), with 60 meeting the remaining study 
inclusion criteria. The primary reason for ineligibility was poor computer literacy 
(N=17). Twenty-five patients were randomised to the supported (N=18) or 
unsupported arm (N=7) with 92% retained at follow-up. No differences in 
psychological distress or cost-effectiveness were apparent between the groups, 
although the study was concerned with feasibility and hence not powered to 
detect differences in mood outcomes.  
 
Future directions and conclusions 
Whilst efforts to evaluate effective treatments for depression have been 
undertaken in dialysis patients recently, it is clear from the current literature that 
we need to be able to increase recruitment into trials, with one option being 
employing more pragmatic or adaptive trial designs. We need to better understand 
and mitigate the barriers to recruitment particularly considering how to include 
patients already receiving treatment (for example drug wash out for anti-
depressant studies) and likewise consider how depression interventions are 
implemented in a way that is acceptable to patients and renal staff.  
For CBT studies, considering how treatments work (i.e. which cognitions 
and behaviours change in therapy that mediate treatment effects) and which 
treatments work from whom (i.e. treatment moderators), is required to improve 
the tailoring of treatment to individuals. Furthermore, there are no studies in 
dialysis patients that have evaluated the combined effects of CBT with anti-
depressants.  
Despite these challenges, it is imperative we invest further into treatments 
trials for depression in order to develop evidence-based treatment guidelines 
specific to individuals on dialysis. In order to deliver future treatment guidelines, 
it remains critical that there is access to renal psychology services that are suitably 
resourced to manage the sometimes complex psychosocial needs of dialysis 
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patients. In doing so it is hoped more patients will receive acceptable and 
efficacious treatment for depression leading to improved mental health and 
quality of life.  
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